The first cervical cancer injection has been prepared by the Serum Institute of India (SII), the largest manufacturer of vaccines in the world. The government and manufacturer said, it will soon be out for purchase nationally and then internationally.
As per the World Health Organization, cervical cancer is the fourth most prevalent illness in women worldwide. In 2020, the disease was estimated with 604,000 new cases and 342,000 fatalities. More than 60% of cases occurred in low and middle-class nations.
At least 70 percent of cervical cancer is caused by two human papillomaviruses (HPV) types: 16 and 18. According to the Indian Department of Biotechnology, the Indian vaccination will also protect against HPV types 6 and 11. The companies that produce HPV vaccinations are Merck & Co. and GSK Plc.
Adar Poonawalla, SII Chief Executive, said in a statement that the development of the vaccine will make the country self-dependent in causing a reduction in female deaths. He said the vaccine will be for sale in the coming months first, for the Indian market and then internationally.
It might cost between 200 and 400 rupees ($2.51 and $5.03). Additionally, the company plans to create 200 million doses in two years. The vaccine will be provided via injection in two doses to children aged 9 to 14, and three doses to individuals aged 15 to 26.
The post First cervical cancer vaccine developed in India appeared first on Hamariweb.com News.